Skip to main content

Silje Watterdal Syversen

Senior researcher
https://orcid.org/0000-0003-2159-3696
View Google Scholar profile
See publications in PubMed

Education

  • Cand.med., University of Oslo (2002)
  • Doctorate at the Department of Clinical Medicine, University of Oslo (2010)

Position

  • Assistant Head of Clinical Research Unit
  • Senior Researcher, Department of Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital
  • Senior Consultant in Rheumatology, Clinic for Rheumatology, Outpatient Clinic and Research, Diakonhjemmet Hospital
  • Project manager RA-DRUM, START and WP1 "Treatment studies"

Field of interest

  • Rheumatology
  • Rheumatoid arthritis
  • Newly occurring arthritis
  • Immunosuppressive medications
  • Personalized medicine
  • Therapeutic drug monitoring
  • Immunogenicity
  • Randomized controlled trials
  • Biomarkers
  • Autoantibodies
  • Epidemiology
  • Vaccine response

Other

  • Co-leader of work package 1 in REMEDY (Treatment studies)
  • Chairman of the Norwegian Rheumatological Association

Email

Telephone

+47 22451500

Visiting address

Diakonhjemmet Hospital
Superintendent's residence
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet Hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP2 - PPhenotyping for personalized medicine

NOR DRUM

The Norwegian study for therapeutic pharmacovigilance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP2 - PPhenotyping for personalized medicine

Nor-vaC

Immunological response to COVID-19 vaccine in patients on immunosuppressive therapy

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Optimized medical interventions

RA-DRUM

Therapeutic drug monitoring in patients with rheumatoid arthritis (RA-DRUM)

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP2 - PPhenotyping for personalized medicine

RIMRA

Rheumatic immune-related adverse events in patients treated with immunotherapy

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP1 - Optimized medical interventions

SQUEEZE

Maximizing the effectiveness of prescription drugs for rheumatoid arthritis 

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.
WP2 - PPhenotyping for personalized medicine

START

Early diagnosis of newly occurring arthritis

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercise ullamco laboris nisi ut aliquip ex ea commodo consequat.

Publications

Publications retrieved from the National Science Archives (NVA):

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials

2024

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

2024

Therapeutic serum level for adalimumab in rheumatoid arthritis: exploratory analyzes of data from a randomized phase III trial

2024

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumor necrosis factor inhibitors: a prospective cohort study

2024

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

2023

T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis

2023

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases

2023

HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis

2023

Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

2023

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

2022

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

2022

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

2022

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

2022

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

2022

Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

2022

Risk factors for anti-drug antibody formation to infliximab: Secondary analyzes of a randomized controlled trial

2022

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

2022

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

2021

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

2021

Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study

2021

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

2021

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

2020

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

2019

Associations between cytokine levels and CYP3A4 phenotype in patients with rheumatoid arthritis

2018

4β-hydroxycholesterol level in patients with rheumatoid arthritis before vs. after initiation of bDMARDs and correlation with inflammatory state

2017

Dickkopf-1 is associated with periarticular bone loss in patients with rheumatoid arthritis

2013

FCRL3-169C/C Genotype Is Associated with Anti-citrullinated Protein Antibody-positive Rheumatoid Arthritis and with Radiographic Progression

2011

Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis

2011

Association Between High Plasma Levels of Hepatocyte Growth Factor and Progression of Radiographic Damage in the Joints of Patients With Rheumatoid Arthritis

2011

The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis

2010

Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs

2010

Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study

2010

Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis

2010

Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study

2009

Cartilage and Bone Biomarkers in Rheumatoid Arthritis: Prediction of 10-year Radiographic Progression

2009

Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up

2009

Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria

2009

Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design

2009

Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers

2009

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study

2008

A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients

2008